Tom Bumol, Ph.D., vice president of biotech discovery research, explained how the company's biotechnology strategy is transforming the Lilly pipeline. "We see more and more that biotech is a key to sustaining pharmaceutical innovation for the future, and Lilly has more than eight decades of experience with biologicals. Today, Lilly is the fifth largest biopharmaceutical company based on biotherapeutic sales, and we are making the necessary investments to strengthen our leadership position. Over the past decade, we have built a new integrated biotechnology infrastructure, from discovery through development, and including delivery devices and manufacturing."
Highlighting Lilly's growing biotech prowess, Dr. Paul remarked, "With the addition of the ImClone cancer antibodies, currently 40 percent of Lilly's clinical stage pipeline and 50 percent of Lilly's late-stage pipeline are comprised of biotechnology-based molecules. Through the ImClone acquisition, we have simultaneously accelerated our emergence as both a biotech and cancer powerhouse, with a pipeline that we believe will provide a continuous flow of high value medicines."
Key late-stage and select mid-stage compounds in each of the company's core therapeutic areas were reviewed by Drs. Paul and Bumol.
Select Pipeline Developments
-- Prasugrel - The company continues to invest heavily in the ongoing
development of prasugrel. Prasugrel, which Lilly is developing with its
partner Daiichi Sankyo, continues to be under review with the U.S. Food and
Drug Administration (FDA) and European Medicines Agency (EMEA) for treatment
of acute coronary syndrome (ACS) in patients undergoing percutaneous coronary
intervention (PCI). Lilly remains in active dialogue with both regulatory
agencies. In addition, prasugrel is also being studied in the TRILOGY trial in
|SOURCE Eli Lilly and Company|
Copyright©2008 PR Newswire.
All rights reserved